(ALIGN) - A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Atrasentan in Patients with IgA Nephropathy at Risk of Progressive Loss of Renal Function
- Ryan, Jessica (Primary Chief Investigator (PCI))
Project: Research
Project: Research